Primary Stroke Prevention

Primary stroke prevention targets individuals with no prior stroke or TIA. The 2024 AHA/ASA guideline emphasizes optimizing cardiovascular health through Life’s Essential 8 — a framework addressing diet, physical activity, weight, sleep, tobacco, blood glucose, blood pressure, and lipids. With over 600,000 first strokes annually in the US and more than half being preventable through risk factor modification, closing the “prevention gap” remains critical.

Risk Assessment

Risk estimation guides preventive treatment decisions. For patients 40–79 years, calculate 10-year ASCVD risk every 1–5 years using the Pooled Cohort Equation (or the newer Predicting Risk of CVD Events equations). In patients with AF, the CHA₂DS₂-VASc score guides anticoagulation decisions. Periodic screening for modifiable risk factors and social determinants of health (food insecurity, transportation barriers) is recommended for all adults ≥18 years.

Life’s Essential 8

Diet Quality

The Mediterranean diet is the only dietary pattern with RCT evidence showing stroke reduction. In a network meta-analysis of 12 trials, Mediterranean dietary programs reduced stroke risk by 7–16 per 1000 patients in those at intermediate-to-high CVD risk. Salt substitution (75% NaCl/25% KCl) reduced stroke in older adults with uncontrolled hypertension (rate ratio 0.78). Supplements including omega-3 fatty acids, vitamins C and E, calcium, and multivitamins have NOT been shown to reduce stroke risk.

Physical Activity

Target at least 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity aerobic activity weekly. Even light physical activity reduces risk compared to sedentary behavior. Stroke risk increases after 3.7 hours/day of sedentary behavior and rises 6% for each additional hour above 6.5 hours/day. Counsel all patients to avoid excessive sedentary time — physical activity only partially mitigates this risk.

Weight and Obesity

Screen with BMI and waist circumference — both independently predict stroke risk. For each 5 kg/m² increase in BMI, stroke risk increases 10%. Bariatric surgery may be considered in class II obesity (BMI ≥35 kg/m²) with observational data showing 33% reduction in cerebrovascular events. GLP-1 receptor agonists now provide an alternative pharmacologic approach with proven stroke reduction.

Blood Glucose

GLP-1 receptor agonists (semaglutide, dulaglutide) reduce stroke in patients with type 2 diabetes. In SUSTAIN-6, semaglutide reduced stroke by 39% versus placebo (HR 0.61). A meta-analysis of 12 RCTs confirmed 27% stroke reduction (RR 0.73). Intensive glycemic control targeting HbA1c ≤6.5% does NOT reduce stroke risk and increases hypoglycemia. SGLT2 inhibitors have NOT been established to reduce stroke.

Blood Pressure

Hypertension is the most potent modifiable risk factor for both ischemic and hemorrhagic stroke. Target SBP/DBP <130/80 mmHg (Class 1, LOE A). First-line agents include thiazides, calcium channel blockers, ACE inhibitors, and ARBs — all are effective. Beta-blockers are inferior to other classes for stroke prevention. Critically, ≥2 antihypertensive medications are required in most patients to achieve BP goals — only ~30% achieve target with monotherapy.

The SPRINT trial demonstrated that intensive BP control (SBP <120 mmHg target) significantly reduces cardiovascular events in high-risk patients without diabetes. BPROAD confirmed these findings specifically in patients with diabetes, showing benefit from intensive BP targets.

Lipids

Statins are recommended for adults meeting 2019 ACC/AHA primary prevention criteria: LDL-C >190 mg/dL, 10-year ASCVD risk ≥20%, or 10-year risk ≥7.5% with risk enhancers. PCSK9 inhibitors (alirocumab, evolocumab) and bempedoic acid for statin-intolerant patients have uncertain stroke prevention benefit in primary prevention. Omega-3 fatty acid supplementation is NOT recommended for stroke prevention.

Tobacco Cessation

Smoking increases stroke risk 2-fold for ischemic stroke, nearly 2-fold for ICH, and 3.5-fold for SAH. Combination pharmacotherapy (varenicline or combination NRT) plus behavioral counseling is most effective for cessation. In hospitalized patients, “opt-out” protocols (default prescription of cessation aids) increase short-term quit rates. The long-term cardiovascular effects of e-cigarettes as smoking cessation aids remain uncertain.

Sleep

Obstructive sleep apnea is associated with increased stroke risk, though CPAP therapy has NOT been shown to reduce stroke in RCTs. Screen for sleep disorders in patients with excessive daytime sleepiness or witnessed apneas, but sleep-focused interventions currently lack stroke outcome data.

Antiplatelet Therapy for Primary Prevention

Aspirin for primary stroke prevention has a notably narrow role:

The ASPREE trial showed no benefit of aspirin 100 mg daily in healthy adults ≥70 years, with increased major bleeding. ARRIVE found no primary endpoint benefit in moderate-risk patients, and ASCEND demonstrated only modest benefit in diabetes that was offset by bleeding risk.

Asymptomatic Carotid Stenosis

For asymptomatic carotid stenosis ≥70%, modern medical therapy (statins, antiplatelet, BP control) reduces annual stroke risk to approximately 1%. Revascularization (CEA or CAS) may be considered in highly selected patients with life expectancy >5 years and perioperative risk <3%, though the benefit over contemporary medical therapy is increasingly marginal. The CREST-2 trial (2025), comparing revascularization with intensive medical management, found carotid stenting reduced 4-year stroke versus medical therapy alone, whereas endarterectomy showed no significant benefit.

Special Populations

Sickle Cell Disease

Children with sickle cell disease and elevated transcranial Doppler velocities (≥200 cm/s) have high stroke risk. The STOP trial demonstrated that chronic red cell transfusions reduce stroke by 92% in this population. Hydroxyurea may be an alternative to transfusion in some patients (SWITCH).

Antiphospholipid Syndrome / Systemic Lupus Erythematosus

Antiplatelet therapy is recommended for patients with antiphospholipid syndrome (APS) or SLE without prior stroke or VTE. For APS patients with prior unprovoked VTE, warfarin (INR 2–3) is preferred over DOACs. The TRAPS trial showed higher thrombotic events with rivaroxaban vs warfarin in triple-positive APS.

Cardiomyopathy

Anticoagulation is NOT indicated for patients with LV systolic dysfunction (EF ≤35-40%) without AF or LV thrombus. WARCEF showed no net benefit of warfarin versus aspirin — modest stroke reduction was offset by increased bleeding. COMMANDER-HF confirmed no benefit with rivaroxaban.

Testosterone Therapy

In men 45–80 years with confirmed hypogonadism, testosterone replacement does NOT increase stroke risk. The TRAVERSE trial (5,246 men with hypogonadism and high CVD risk) found no difference in major cardiovascular events or nonfatal stroke with transdermal testosterone.

Key Trial Comparison

References

1. Bushnell C, et al. 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the AHA/ASA. Stroke. 2024;55:e344-e424.
2. Lloyd-Jones DM, et al. Life’s Essential 8: Updating and Enhancing the AHA’s Construct of Cardiovascular Health. Circulation. 2022;146:e18-e43.
3. Arnett DK, et al. 2019 ACC/AHA Guideline on the Primary Prevention of CVD. Circulation. 2019;140:e596-e646.